| Schedule of common stock issued roll forward |
The following table represents a share reconciliation of the Company’s common stock issued for the periods presented: | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Common stock: | | | | | | | | | Balance, beginning of period | | 211,059,707 | | 197,536,271 | | 207,785,762 | | 195,028,207 | Shares issued for stock options exercised | | 816 | | 15,870 | | 8,710 | | 72,282 | Agent growth incentive stock-based compensation | | 1,002,375 | | 859,028 | | 1,634,649 | | 1,305,685 | Agent equity stock-based compensation | | 4,477,051 | | 3,038,414 | | 7,087,098 | | 5,043,409 | Other stock-based compensation | | 29,120 | | - | | 52,850 | | - | Other share activity | | (2,715,349) | | - | | (2,715,349) | | - | Balance, end of period | | 213,853,720 | | 201,449,583 | | 213,853,720 | | 201,449,583 |
|
| Changes in the Company's stock compensation liability |
The following table illustrates changes in the Company’s stock-based compensation liability for the periods presented: | | | | | Amount | Balance, December 31, 2024 | | $ 5,045 | Stock grant liability increase year to date | | 2,736 | Stock grants reclassified from liability to equity year to date | | (1,999) | Balance, December 31, 2025 | | $ 5,782 | Stock grant liability increase year to date | | 2,353 | Stock grants reclassified from liability to equity year to date | | (1,315) | Balance, June 30, 2026 | | $ 6,820 |
|